Insider · CIK 0001433316
Knuettel Francis II
directorceocfoofficer
Files at BLNE (Beeline Holdings, Inc.), PTHS (Pelthos Therapeutics Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | BLNE Beeline Holdings, Inc. | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 130,000 | 32 d ago |
| Dec 16, 2025 | BLNE Beeline Holdings, Inc. | AGrant or award Common Stock | +30,000 | $0.00 | $0 | 70,000 | Dec 17, 2025 |
| Oct 2, 2025 | BLNE Beeline Holdings, Inc. | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 40,000 | Oct 6, 2025 |
| Jul 2, 2025 | PTHS Pelthos Therapeutics Inc. | AGrant or award Restricted Stock Unitsderivative | +33,472 | - | - | 33,472 | Jul 7, 2025 |
| Jul 2, 2025 | PTHS Pelthos Therapeutics Inc. | AGrant or award Stock Optionderivative | +102,000 | - | - | 145,074 | Jul 7, 2025 |
| Jul 1, 2025 | PTHS Pelthos Therapeutics Inc. | CConversion Common Stockindirect: By Camden Capital LLC | +10,000 | $10.00 | $100k | 10,000 | Jul 3, 2025 |
| Jul 1, 2025 | PTHS Pelthos Therapeutics Inc. | JOther Series A Convertible Preferred Stockderivativeindirect: See footnote | +10,000 | $0.00 | $0 | 10,000 | Jul 3, 2025 |
| Jul 1, 2025 | PTHS Pelthos Therapeutics Inc. | CConversion Series A Convertible Preferred Stockderivativeindirect: See footnote | -10,000 | $0.00 | $0 | 0 | Jul 3, 2025 |
| Apr 11, 2025 | PTHS Pelthos Therapeutics Inc. | AGrant or award Stock Optionderivative | +53,988 | - | - | 430,736 | Apr 15, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.